Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses
详细信息 查看全文
- 作者：Julian C. van Capelleveen ; MDa ; John J.P. Kastelein ; MD ; PhDa ; b ; j.s.jansen@amc.uva.nl" class="auth_mail" title="E-mail the corresponding author ; Aeilko H. Zwinderman ; PhDc ; Sander J.H. van Deventer ; MD ; PhDb ; d ; Heidi L. Collins ; PhDe ; Steven J. Adelman ; PhDe ; Patrick Round ; PhDb ; f ; John Ford ; PhDb ; f ; Daniel J. Rader ; MD ; PhDg ; G. Kees Hovingh ; MD ; PhDa
- 关键词：TA-8995 ; CETP inhibitor ; Cholesterol efflux capacity ; HDL ; Pre-Beta1 HDL
- 刊名：Journal of Clinical Lipidology
- 出版年：2016
- 出版时间：September-October 2016
- 年：2016
- 卷：10
- 期：5
- 页码：1137-1144.e3
- 全文大小：399 K
文摘
- •
Cholesterol efflux capacity (CEC) is inversely associated with CAD risk.
- •
The CETP inhibitor TA-8995 increases total, abca1 and non-ABCA1 CEC.
- •
TA-8995 increases pre-Beta1 HDL particles, the main acceptor for ABCA1 CEC.
- •
Total CEC increase was associated with pre-Beta1 increase but not with HDL-C increase.